Kim Lennart Dueholm
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Kim Lennart Dueholm
| Entità | Tipo di entità | Settore Industriale | |
|---|---|---|---|
University of Copenhagen
73
| College/University | Other Consumer Services | 73 |
| Public Company | Pharmaceuticals: Major | 16 | |
Novo Ventures 1 A/S
 Novo Ventures 1 A/S Investment ManagersFinance Novo Ventures (Novo Ventures) is a venture capital operating division of Novo Nordisk Fonden. It engages in investment activities. The firm was established in 1999, and is headquartered in Hellerup, Denmark.
14
| Operating Division | Investment Managers | 14 |
University of Southern Denmark
4
| College/University | Other Consumer Services | 4 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kim Lennart Dueholm tramite i suoi contatti personali
| Società | Settore | Persone collegate | Posizione principale |
|---|---|---|---|
| KERYX BIOPHARMACEUTICALS | Pharmaceuticals: Major | Chairman President | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director/Board Member Director/Board Member Director/Board Member Corporate Officer/Principal | |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Medical Specialties | Director of Finance/CFO Corporate Officer/Principal Comptroller/Controller/Auditor General Counsel | |
| H. LUNDBECK A/S | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Sales & Marketing Public Communications Contact | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| VELOXIS PHARMACEUTICALS A/S | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member Founder Director/Board Member Corporate Officer/Principal | |
Thesan Pharmaceuticals, Inc.
 Thesan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thesan Pharmaceuticals, Inc. provides novel therapeutics for disorders of the skin. The company focuses on the discovery and development of new chemical entities that provide improved treatment options to patients. Thesan Pharmaceuticals was founded in 2011 by Edward P. Monaghan and is headquartered in Carlsbad, CA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| DANSKE BANK A/S | Major Banks | Chief Executive Officer President | |
| COLOPLAST A/S | Medical Specialties | Corporate Officer/Principal Director/Board Member | |
| NTG NORDIC TRANSPORT GROUP A/S | Trucking | Corporate Officer/Principal Chairman | |
Novo Nordisk Fonden
 Novo Nordisk Fonden Investment Trusts/Mutual FundsMiscellaneous Novo Nordisk Fonden provides basis for the commercial and research activities conducted by the companies. It also supports scientific and humanitarian purposes activities. It awards grants for research within biomedicine, biotechnology, general practice and family medicine, nursing, and art history at public research institutions. It bridges gap between the discoveries made by researchers in biomedicine and biotechnology and their commercial application. The company was founded by August Krogh, Marie Krogh, Harald Pedersen, Hans Christian Hagedorn, August Kongsted and Thorvald Pedersen in 1922 and is headquartered in Hellerup, Denmark. | Investment Trusts/Mutual Funds | Chairman Chief Executive Officer Chief Executive Officer | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Chairman Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Director of Finance/CFO Chief Investment Officer Chief Executive Officer | |
| BIOPORTO A/S | Medical Specialties | President Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Masters Business Admin Undergraduate Degree | |
| Suffolk University | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin | |
| Copenhagen Business School | College/University | Undergraduate Degree Graduate Degree Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Aarhus | College/University | Doctorate Degree Graduate Degree | |
| Technical University of Denmark | College/University | Graduate Degree Graduate Degree Graduate Degree Undergraduate Degree Corporate Officer/Principal Graduate Degree Masters Business Admin Doctorate Degree | |
7TM A/S
 7TM A/S Pharmaceuticals: MajorHealth Technology 7TM A/S performs research and development within biotechnology. It engages in clinical development of drugs focusing on obesity and gastrointestinal diseases. The company was founded by Thue Walter Schwartz, Anders Fink Vadsholt, Mette Kirstine Agger, Christian Ellebæk Elling, and Peter Moldt on January 1, 2000 and is headquartered in Hørsholm, Denmark. | Pharmaceuticals: Major | Director/Board Member Founder | |
Azanta Danmark A/S
 Azanta Danmark A/S Pharmaceuticals: MajorHealth Technology Azanta Danmark A/S operates as biopharmaceutical company developing treatments for women's health indications and for orphan oncology. The firm develops protein therapeutics within oncology and infectious diseases. The company was founded by Martin N. Bonde, Jens Christian Jensenius, Steffen Thiel, and R. Alan B. Ezekowitz in 2000 and is headquartered in Valby, Denmark. | Pharmaceuticals: Major | Director/Board Member President | |
Novo Nordisk, Inc.
 Novo Nordisk, Inc. BiotechnologyHealth Technology Novo Nordisk, Inc. operates diabetes care company. It offers biopharmaceuticals, chronic weight management, human growth hormone therapy and hemophilla management services. The firm also provides rare bleeding disorders, growth hormone related disorders, and women's health. The company was founded in 1982 and is headquartered in Plainsboro, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer President Director/Board Member | |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology F2G Ltd. provides novel drugs for the treatment of life-threatening systemic fungal diseases. It primarily focuses on developing an F3 series of anti mould compound, which is an antifungal agent that acts through a mechanism different from marketed drugs. The company was founded in 1998 and is headquartered in Manchester, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Celltrix AB
 Celltrix AB Medical SpecialtiesHealth Technology Celltrix AB manufactures medical devices. It develops novel and injectable dermal filler for reconstructive cosmetic surgery, based on microbeads of cross-linked gelatine. The company was founded in December 2003 by Kjell Gösta Conny Nilsson and is headquartered in Malmö, Sweden. | Medical Specialties | Director/Board Member Director/Board Member | |
Novo Seeds
 Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Investor Director of Investments | |
| NNIT A/S | Information Technology Services | Corporate Officer/Principal Chief Executive Officer Director/Board Member | |
Epsilon-3 Bio Ltd
 Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Other | Founder Director/Board Member | |
Novo Ventures (US), Inc.
 Novo Ventures (US), Inc. Investment ManagersFinance Novo Ventures (US), Inc. is a venture capital firm located in San Francisco. The firm is a subsidiary of Novo A/S and their ultimate parent is Novo Nordisk Fonden. | Investment Managers | Corporate Officer/Principal Private Equity Investor Private Equity Investor | |
Copenhagen Infrastructure Partners P/S
 Copenhagen Infrastructure Partners P/S Investment ManagersFinance Copenhagen Infrastructure Partners P/S (CIP) is a private equity firm founded- in 2012 by Jakob Baruël Poulsen, Christian Skakkebæk, Torsten Lodberg Smed, and Rune Bro Róin. The firm is headquartered in Copenhagen, Denmark. | Investment Managers | Private Equity Investor Founder Chief Executive Officer Private Equity Investor | |
Anokion SA
 Anokion SA Medical/Nursing ServicesHealth Services Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland. | Medical/Nursing Services | Director/Board Member Chairman | |
| BOLT BIOTHERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
Kanyos Bio, Inc.
 Kanyos Bio, Inc. Pharmaceuticals: MajorHealth Technology Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
Nuvelution Pharma, Inc.
 Nuvelution Pharma, Inc. BiotechnologyHealth Technology Nuvelution Pharma, Inc. provides solutions for R&D companies in the pharmaceutical and biotech industries. The firm leverages its knowledge, experience and relationships in the Pharma and Biotech industries to deploy capital in risk-sharing collaborations with companies where product development can be facilitated by both capital and human resources, making this model an essential tool for pharma and biotech companies to bring products to the market. The company was founded by Sanford S. Zweifach and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Director/Board Member | |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Outpost Medicine, Inc.
 Outpost Medicine, Inc. Pharmaceuticals: MajorHealth Technology Outpost Medicine LLC develops therapeutics for the treatment of urologic and gynecologic disorders. The company was founded by David Socks and Tachi Yamada in 2016 and is headquartered in Lexington, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| INOZYME PHARMA, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Novo Holdings A/S (Investment Company)
 Novo Holdings A/S (Investment Company) Financial ConglomeratesFinance Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets. | Financial Conglomerates | Corporate Officer/Principal Corporate Officer/Principal | |
| HARMONY BIOSCIENCES HOLDINGS, INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Harmony Biosciences LLC
 Harmony Biosciences LLC Pharmaceuticals: MajorHealth Technology Harmony Biosciences LLC operates as a biopharmaceutical company which develops therapies to help patients with unmet medical needs. It provides novel treatment options to patients with orphan and rare conditions, with an emphasis on central nervous system disorders. The company is headquartered in Plymouth Meeting, PA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Nordic Alpha Partners ApS
 Nordic Alpha Partners ApS Investment ManagersFinance Nordic Alpha Partners ApS (Nordic Alpha Partners) is a private equity firm founded by Rasmus Hagstad Lund, Troels Oberg and Laurits Mathias Bach Sorensen in 2017. The firm is headquartered in Hellerup, Denmark. | Investment Managers | Founder Consultant / Advisor | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| ALIGOS THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member |
Statistiche
Distribuzione geografica
| Stati Uniti | 23 |
| Danimarca | 23 |
| Regno Unito | 4 |
| Canada | 2 |
| Svezia | 2 |
Settori
| Health Technology | 35 |
| Finance | 8 |
| Consumer Services | 6 |
| Transportation | 2 |
| Miscellaneous | 2 |
Posizioni
| Director/Board Member | 503 |
| Corporate Officer/Principal | 182 |
| Chairman | 143 |
| Chief Executive Officer | 104 |
| Independent Dir/Board Member | 81 |
Contatti più connessi
| Insiders | |
|---|---|
| Eivind Kolding | 50 |
| Arne Gerlyng-Hansen | 46 |
| Martin Edwards | 38 |
| Jack Nielsen | 38 |
| Muneer Satter | 35 |
| Michael Wyzga | 31 |
| Nanna Liebach Lüneborg | 29 |
| Peter Bisgaard | 28 |
| John M. Rice | 27 |
| Lars Dybkjær | 26 |
| Peter Moldt | 25 |
| Thomas Dyrberg | 24 |
| Rasmus Lund | 24 |
| Jan Ulf Sigvar J. Johansson | 23 |
| Maxine Gowen | 23 |
- Borsa valori
- Insiders
- Kim Lennart Dueholm
- Connessioni Società
